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Abstract Thrombopoietin (TPO), or c-MPL ligand, is the
primary regulator of megakaryocyte and platelet production.
TPO receptors expressed on human megakaryocytes derived
from peripheral blood (PB) and cord blood (CB) progenitors
cultured in the presence of TPO have now been analyzed
quantitatively. Like those on human PB platelets, TPO receptors
on the cultured megakaryocytes exhibited a molecular mass of
approximately 80 kDa. Various characteristics of PB- and CB-
derived megakaryocytes indicated that the former were more
mature than the latter. Both PB- and CB-derived megakaryo-
cytes expressed a single class of high-affinity TPO receptors,
with 1933 þ 772 (n = 3) and 184 þ 48 (n = 4) sites per cell,
respectively. These data indicate that the number of TPO
receptors on human megakaryocytes increases with cell matura-
tion.
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1. Introduction
Thrombopoietin (TPO), or c-MPL ligand, is the recently
isolated hematopoietic factor that primarily regulates mega-
karyopoiesis and platelet production [1^5]. In vitro, recombi-
nant TPO (rTPO) stimulates the proliferation and maturation
of megakaryocyte progenitor cells [6^10]. In addition to acting
on megakaryopoiesis, rTPO enhances the growth of commit-
ted erythroid progenitors [11] and primitive hematopoietic
progenitors [12]. rTPO also acts on platelets to activate several
signal transduction pathways [13,14] and to enhance their
function [15]. Furthermore, the administration of rTPO to
mice or non-human primates markedly increases both platelet
production and the numbers of megakaryocytes and their
progenitors [3,16] as well as those of other hematopoietic pro-
genitors in the bone marrow [16,17].
These e¡ects of TPO are mediated through interaction with
its speci¢c cell surface receptor, c-MPL [18], originally identi-
¢ed by its homology to the product of the v-mpl oncogene of
myeloproliferative leukemia virus. The human c-MPL protein
comprises 635 amino acids, and does not contain consensus
sequences for kinase-related or nucleotide-binding domains in
its cytoplasmic region [18]. Transcripts encoding c-MPL have
been identi¢ed in normal CD34 cells [19], in megakaryocytic
cell lines [19,20], and in blast cells from individuals with acute
myelogenous leukemia [21,22].
Recent studies have shown that platelets express a small
number of high-a⁄nity TPO receptors [23^25] with a molec-
ular size of 97 kDa, as assessed by cross-linking analysis [24].
Furthermore, it has been suggested that the plasma concen-
tration of TPO is regulated through the binding of TPO to
receptors on circulating platelets [23,26]. However, little is
known about TPO receptors on megakaryocytes because of
the di⁄culty in obtaining a su⁄cient number of puri¢ed cells
for detailed studies. We have now performed a quantitative
analysis of TPO receptors on human megakaryocytes pro-
duced by culturing megakaryocyte progenitors obtained
from two di¡erent sources in the presence of recombinant
human TPO (rhTPO).
2. Materials and methods
2.1. Cytokines
Full-length rhTPO and recombinant mouse interleukin-3 (rmIL-3)
were expressed in Chinese hamster ovary cells and in Escherichia coli,
respectively, and were puri¢ed to homogeneity by the Production
Technology Group at Kirin. Protein concentrations were determined
by analysis of amino acid composition.
2.2. Platelet preparation
Blood was collected by venipuncture from healthy volunteers into a
syringe containing 10% acid-citrate-dextrose anticoagulant and was
gently mixed. Within 1 h after blood collection, platelet-rich plasma
(PRP) was obtained by centrifuging the whole blood at 200Ug for 20
min at room temperature. For preparation of washed platelets, plate-
lets in the PRP were washed twice with binding bu¡er (see Section
2.4). For preparation of gel-¢ltered platelets, PRP was fractionated on
a Sepharose CL-2B (Pharmacia, Uppsala, Sweden) column that had
been equilibrated with binding bu¡er, as previously described [27].
2.3. Cultured megakaryocytes and megakaryocytic cell line
Low-density mononuclear cells from human umbilical cord blood
(CB) and CD34 cells from peripheral blood (PB) were prepared as
described [28], and cultured for 12^14 days in the presence of rhTPO
(10 ng/ml) in serum-depleted medium [Iscove’s modi¢ed Dulbecco’s
medium (IMDM) (Gibco, Grand Island, NY) supplemented with 1%
bovine serum albumin (BSA), 1.7 WM recombinant human insulin
(Sigma, St. Louis, MO), human transferrin (300 Wg/ml) (Boehringer
Mannheim, Mannheim, Germany), and 50 WM 2-mercaptoethanol
(Merck, Darmstadt, Germany)]. The resultant cells were highly en-
riched for megakaryocytes, as assessed by £ow cytometry for the
expression of CD41 [28]. Megakaryocyte ploidy was analyzed by
£ow cytometry as described [28]. To yield su⁄cient numbers of CB-
derived megakaryocytes for quantitative analysis of TPO receptors,
low-density mononuclear cells were used as the starting cell popula-
tion in place of CD34 cells. Megakaryocytes grown from the two
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di¡erent cell fractions showed similar ploidy distribution (Table 2 and
[28]), indicating a similar stage of cell di¡erentiation.
Dami cells, a human megakaryoblastic cell line [29], were obtained
from American Type Culture Collection (Rockville, MD) and main-
tained in IMDM supplemented with 10% heat-inactivated horse se-
rum. For di¡erentiation of Dami cells, they were incubated for 20
days with 5 nM phorbol ester 12-O-tetradecanoyl phorbol 13-acetate
(TPA).
2.4. Equilibrium binding analysis
rhTPO (3 Wg) was labeled with 125I by incubation in a ¢nal volume
of 28 Wl with 18.5 MBq of Na125I (Amersham, Braunschweig, Ger-
many), lactoperoxidase (0.45 U/ml) (Calbiochem, La Jolla, CA), glu-
cose oxidase (0.05 U/ml) (Wako, Tokyo, Japan), 9.2 WM NaI, and
0.24% L-D-(+)-glucose (Sigma). Free iodide was removed by passage
through a PD-10 gel-¢ltration column (Pharmacia). The speci¢c ac-
tivity of 125I-rhTPO was determined by self-displacement analysis with
FDCP-hMpl5 cells which are mIL-3-dependent mouse myeloid leuke-
mia FDCP-2 cells genetically engineered to express human c-MPL
constitutively [30].
Before binding experiments with CB- and PB-derived megakaryo-
cytes, the cells were washed twice with IMDM containing 10% fetal
bovine serum (FBS) and resuspended in the same medium. They were
further incubated for 6 h at 37‡C without the addition of rhTPO to
remove rhTPO that bound to c-MPL on the cell surface during the
primary culture, as reported for quantitative analysis of the erythro-
poietin (EPO) receptor on EPO-responsive murine cell lines [31]. The
cultured megakaryocytes were then passed through a 10% glucose
solution by centrifugation at 250Ug. To quantify the binding a⁄nity
and number of TPO receptors, we incubated platelets or megakaryo-
cytes for 1 h at 37‡C with 125I-rhTPO, in the absence or presence of a
100-fold or more excess of unlabeled rhTPO, in binding bu¡er
[Hanks’ balanced salt solution without phenol red, CaCl2, MgCl2,
and MgSO4 (modi¢ed HBSS) (Gibco), supplemented with 0.35%
BSA, 20 mM HEPES, 5 mM EDTA, and 0.02% NaN3]. Bound radio-
activity was separated from unbound 125I-rhTPO by centrifugation of
each sample through bovine serum. Non-speci¢c binding was deter-
mined by incubating the cells with 125I-rhTPO in the presence of
unlabeled ligand. The binding data were subjected to Scatchard anal-
ysis.
2.5. A⁄nity cross-linking
Washed platelets and PB-derived megakaryocytes were incubated in
binding bu¡er for 1 h at 37‡C with 125I-rhTPO in the absence or
presence of a 200-fold excess of unlabeled rhTPO. After washing twice
with ice-cold PBS, the cells were incubated for 30 min at 4‡C with
4 WM BS3 (Pierce, Rockford, IL) in modi¢ed HBSS. The cross-linking
reaction was quenched by the addition of 0.2 M glycine solution.
After two washes with ice-cold PBS, the cells were solubilized at
4‡C for 30 min in lysis bu¡er [modi¢ed HBSS containing 1% Triton
X-100, 150 mM NaCl, 1 mM phenylmethylsulfonyl £uoride, aprotinin
(0.3 TIU/ml), 2 mM EDTA, and 2 mM EGTA]. The lysates were
centrifuged at 15 000Ug for 20 min to remove nuclei and other debris,
and the resulting supernatants were subjected to SDS-polyacrylamide
gel electrophoresis on a 6% gel under reducing conditions. A⁄nity-
labeled protein was detected by autoradiography of the dried gels.
3. Results
3.1. Molecular size of TPO receptors on platelets and
megakaryocytes
The molecular sizes of TPO receptors on washed platelets
and PB-derived megakaryocytes were compared by cross-link-
ing 125I-rhTPO to the receptors with the use of the homobi-
functional cross-linker BS3. A labeled complex of V170 kDa
was apparent when washed platelets or PB-derived megakar-
yocytes were incubated with 125I-rhTPO in the absence of
unlabeled rhTPO, but not in its presence (Fig. 1). Given
that the molecular mass of rhTPO is 80^100 kDa, the TPO
receptors on both cell types showed a molecular size of ap-
proximately 80 kDa.
3.2. Quantitative analysis of TPO receptors on human platelets
and megakaryocytes
The speci¢c TPO receptors on platelets obtained from nor-
mal human PB were characterized by Scatchard analysis of
equilibrium binding of 125I-rhTPO. Normal human platelets
expressed a single class of high-a⁄nity TPO receptors as pre-
viously described [21,22]. Washed human platelets exhibited
22 þ 7 receptors per cell, with a Kd of 28 þ 8 pM (n = 10) (Ta-
ble 1). Similar results were obtained with gel-¢ltered platelets
[23 þ 12 receptors per cell, with a Kd of 50 þ 39 pM (n = 5)].
Culture of CB mononuclear cells or PB CD34 cells in the
presence of rhTPO for 12^14 days resulted in selective expan-
sion of megakaryocytes (87.1^97.3% and 92.1^95.8% CD41
cells, respectively) (Table 2). Cell size, ploidy, and expression
of CD42 antigen were greater for PB-derived than for CB-
derived megakaryocytes (Table 2). Scatchard analysis revealed
that CB-derived megakaryocytes expressed 184 þ 48 TPO re-
ceptors per cell, with a Kd of 125 þ 12 pM (n = 4) (Table 3),
whereas the corresponding values for PB-derived megakaryo-
cytes were 1933 þ 772 receptors per cell and 90 þ 14 pM
(n = 3), respectively (Fig. 2, Table 3).
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Fig. 1. Cross-linking of 125I-rhTPO to human PB-derived megakar-
yocytes (A) and platelets (B). PB-derived megakaryocytes and
washed platelets were exposed to the cross-linker BS3 after incuba-
tion with 125I-rhTPO in the absence (lane 1) or presence (lane 2) of
a 200-fold excess of unlabeled rhTPO. Cell lysates were analyzed by
SDS-polyacrylamide gel electrophoresis and autoradiography. The
upper band represents the cross-linked complex and the lower band
is free 125I-rhTPO. The positions of molecular size markers are indi-
cated in kilodaltons.
Table 1
Analysis of TPO receptors on normal human washed and gel-¢ltered platelets
Platelet preparation Receptors per cell Kd (pM) n
Mean þ S.E. Range Mean þ S.E. Range
Washed 22 þ 7 15^35 28 þ 8 20^41 10
Gel-¢ltered 23 þ 12 15^43 50 þ 39 26^112 5
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3.3. E¡ect of di¡erentiation on the number of TPO receptors
on Dami cells
Finally, we investigated the e¡ect of culture of Dami cells
for 20 days with TPA on the expression of TPO receptors.
TPA induced megakaryocytic di¡erentiation of Dami cells as
characterized by an increase in both size and ploidy (data not
shown). Scatchard analysis of equilibrium binding of 125I-
rhTPO to TPA-treated and untreated Dami cells revealed
the presence of 3508 and 1351 receptors per cell, respectively
(Fig. 3). Thus, megakaryocytic di¡erentiation of Dami cells
was associated with an increase in the number of TPO recep-
tors.
4. Discussion
Analysis of the molecular events that control the develop-
ment of hematopoietic cells depends on the availability of
su⁄cient numbers of puri¢ed cells. In this study, we have
examined the expression of TPO receptors on both human
PB platelets and cultured megakaryocytes. Selective enrich-
ment of megakaryocytes was achieved by culture of CB-
and PB-derived hematopoietic cells in the presence of TPO
as the sole hematopoietic factor. These highly enriched prep-
arations allowed us to conduct quantitative analysis of TPO
receptors on human megakaryocytes. Equilibrium binding ex-
periments showed that megakaryocytes as well as platelets
express a single class of high-a⁄nity TPO receptors and that
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Table 2
Analysis of purity and maturation of CB- and PB-derived megakaryocytes (four and two preparations, respectively)
Source of megakaryocytes Perimeter (Wm) CD41 (%) CD42b (%) Ploidy (%)
2N 4N 8N s 8N
Cord blood ND 87.1 46.8 70.1 10.3 3.5 1.4
105 97.3 74.8 75.4 11.4
ND 92.7 66.8 89.3 7.8
ND 88.9 70.3 90 9.9
Peripheral blood 169 95.8 85.8 32.2 23.2 28.9 12.4
125 92.1 75.3 56.4 21.9 14.5 5
ND, not determined.
Fig. 2. Scatchard analysis of 125I-rhTPO binding to CB-derived (A)
and PB-derived (B) megakaryocytes. Cells were incubated with vari-
ous concentrations of 125I-rhTPO in the absence or presence of a
100-fold or more excess of unlabeled rhTPO for 1 h at 37‡C. Data
represent Scatchard analysis of representative experiments.
Fig. 3. Scatchard analysis of 125I-rhTPO binding to Dami cells cul-
tured in the absence (A) or presence (B) of TPA. Cells were cul-
tured for 20 days in the absence or presence of 5 nM TPA, after
which the binding of 125I-rhTPO was assessed by Scatchard analysis.
Data are from a representative experiment and revealed 1351 (A)
and 3508 (B) receptors per cell.
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the number of TPO receptors on megakaryocytes increases as
the cells mature. Furthermore, cross-linking analysis indicated
that the molecular mass of TPO receptors on human mega-
karyocytes is similar to that of those on platelets.
Whereas Fielder et al. [25] showed that 125I-rhTPO was
cleaved and degraded to multiple polypeptide fragments on
incubation with human platelets, under our experimental con-
ditions human platelets that had been incubated with 125I-
rhTPO displayed only the full-length radioligand (data not
shown). Therefore, our a⁄nity analysis directly re£ects the
interaction of c-MPL with full-length TPO, and not that
with truncated molecules. In addition, the truncation of
rhTPO by thrombin-mediated cleavage [32] should not occur
in our system because platelets and megakaryocytes were in-
cubated with 125I-rhTPO in the absence of free Ca ions, which
blocks thrombin-catalyzed cleavage. Equilibrium binding ex-
periments with washed platelets revealed a single class of high-
a⁄nity TPO receptors with V20 receptors per cell, similar to
results obtained with gel-¢ltered platelets, which are treated
more gently during preparation. Thus, expression of TPO
receptors by the washed platelets did not appear to be a¡ected
by treatment during their preparation. Previous studies with
washed human platelets also detected a single class of high-
a⁄nity TPO receptors with V30 receptors per cell [24,25].
However, murine platelets have been shown to display 220
TPO receptors per cell [23]. The di¡erence in species or in
experimental techniques likely contributes to these di¡erent
results.
Scatchard analysis of our binding data showed that PB-
derived megakaryocytes express a greater number of TPO
receptors than do CB-derived megakaryocytes. In addition,
TPA-induced di¡erentiation of Dami cells was accompanied
by an increase in the number of TPO receptors on these cells.
These observations indicate that TPO receptor expression in-
creases with terminal maturation of megakaryocytes. Expres-
sion of the EPO receptor has been shown to change with
di¡erentiation and maturation of cells committed to the eryth-
roid lineage. The EPO receptor has been detected on burst-
forming unit-erythroids, which are early, EPO-responsive pro-
genitors. The number of EPO receptors increases with cell
maturation, reaching a peak at the colony-forming unit-eryth-
roid and proerythroblast stages, and thereafter decreases with
further maturation [31,33].
TPO stimulates not only proliferation of megakaryocyte
progenitor cells but also generation of polyploid mature meg-
akaryocytes which result in formation of extended cytoplas-
mic processes termed proplatelets. The physiological signi¢-
cance of the maturation-associated increase in the number
of TPO receptors on megakaryocytes is unclear. However,
since the formation of proplatelets from mature megakaryo-
cytes has been shown to be inhibited by the addition of TPO
[10], TPO receptors on mature megakaryocytes may partici-
pate in the regulation of platelet production. In addition, the
plasma concentration of TPO is thought to be regulated, to
some extent, by TPO receptors on megakaryocytes [34]. Our
data indicate that such regulation of the plasma TPO concen-
tration might be possible given the expression of high-a⁄nity
TPO receptors by these cells.
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